Your browser is no longer supported. Please, upgrade your browser.
Provention Bio, Inc.
Index- P/E- EPS (ttm)-1.84 Insider Own19.84% Shs Outstand56.53M Perf Week-27.50%
Market Cap617.04M Forward P/E- EPS next Y-1.48 Insider Trans0.00% Shs Float48.16M Perf Month-35.64%
Income-98.60M PEG- EPS next Q-0.46 Inst Own38.40% Short Float5.87% Perf Quarter-55.43%
Sales- P/S- EPS this Y-76.90% Inst Trans0.56% Short Ratio2.52 Perf Half Y-44.71%
Book/sh1.96 P/B4.08 EPS next Y30.20% ROA-73.80% Target Price- Perf Year-7.51%
Cash/sh1.58 P/C5.07 EPS next 5Y- ROE-81.90% 52W Range8.60 - 20.05 Perf YTD-52.77%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-60.10% Beta-
Dividend %- Quick Ratio7.60 Sales past 5Y- Gross Margin- 52W Low-6.98% ATR1.00
Employees59 Current Ratio7.60 Sales Q/Q- Oper. Margin- RSI (14)25.07 Volatility12.27% 8.23%
OptionableYes Debt/Eq0.00 EPS Q/Q-160.90% Profit Margin- Rel Volume17.32 Prev Close9.73
ShortableYes LT Debt/Eq0.00 EarningsFeb 25 BMO Payout- Avg Volume1.12M Price8.00
Recom1.70 SMA20-31.93% SMA50-38.28% SMA200-42.16% Volume19,439,473 Change-17.82%
Apr-09-21Reiterated SVB Leerink Outperform $26 → $16
Apr-09-21Downgrade RBC Capital Mkts Outperform → Sector Perform $27 → $25
Jun-16-20Reiterated H.C. Wainwright Buy $20 → $26
Jun-04-20Initiated RBC Capital Mkts Outperform $25
Jun-04-20Initiated Oppenheimer Outperform $29
Jan-24-20Initiated Cantor Fitzgerald Overweight $25
Jun-26-19Reiterated H.C. Wainwright Buy $8 → $20
Jun-10-19Initiated Chardan Capital Markets Buy $20
Feb-22-19Initiated SVB Leerink Outperform $6
Apr-09-21 07:39AM  
Apr-08-21 04:01PM  
Mar-26-21 07:27AM  
Mar-04-21 07:30AM  
Mar-03-21 04:01PM  
Feb-25-21 01:01PM  
Feb-19-21 05:59AM  
Feb-18-21 02:18PM  
Feb-17-21 04:00PM  
Jan-28-21 07:30AM  
Jan-27-21 06:50AM  
Jan-13-21 07:03PM  
Jan-12-21 04:26PM  
Jan-06-21 04:05PM  
Jan-04-21 07:00AM  
Dec-21-20 07:30AM  
Dec-15-20 07:30AM  
Dec-10-20 12:02PM  
Dec-08-20 08:55AM  
Dec-04-20 08:14AM  
Nov-25-20 08:31AM  
Nov-11-20 07:30AM  
Nov-10-20 12:42PM  
Nov-06-20 07:30PM  
Nov-05-20 07:00AM  
Nov-02-20 07:30AM  
Oct-29-20 07:30AM  
Oct-20-20 12:52PM  
Oct-01-20 07:30AM  
Sep-30-20 04:05PM  
Sep-08-20 08:55AM  
Aug-31-20 07:30AM  
Aug-25-20 10:00AM  
Aug-19-20 10:46AM  
Aug-13-20 07:38AM  
Aug-11-20 07:00AM  
Aug-06-20 07:00AM  
Aug-03-20 04:05PM  
Jul-30-20 07:00AM  
Jul-02-20 09:15AM  
Jun-30-20 04:30PM  
Jun-29-20 07:00AM  
Jun-22-20 04:01PM  
Jun-19-20 10:26AM  
Jun-17-20 10:16PM  
Jun-16-20 04:01PM  
Jun-15-20 05:02PM  
May-28-20 07:00AM  
May-20-20 07:00AM  
May-18-20 07:00AM  
May-08-20 07:30PM  
Apr-30-20 07:00AM  
Apr-16-20 07:00AM  
Apr-01-20 09:09AM  
Mar-21-20 08:54AM  
Mar-17-20 08:48AM  
Mar-16-20 04:05PM  
Mar-12-20 07:05AM  
Mar-05-20 07:00AM  
Feb-19-20 07:00AM  
Feb-05-20 12:41PM  
Jan-23-20 06:30AM  
Jan-08-20 07:00AM  
Dec-30-19 02:44PM  
Dec-17-19 05:19PM  
Dec-12-19 07:00AM  
Dec-05-19 06:15AM  
Dec-04-19 12:00PM  
Nov-21-19 07:32AM  
Nov-05-19 04:05PM  
Oct-29-19 12:52PM  
Oct-24-19 07:00AM  
Oct-22-19 07:00AM  
Sep-26-19 07:00AM  
Sep-25-19 07:00AM  
Sep-24-19 07:00AM  
Sep-19-19 07:39AM  
Sep-18-19 08:26PM  
Aug-27-19 03:30PM  
Aug-20-19 07:00AM  
Aug-09-19 08:15AM  
Aug-08-19 07:00AM  
Aug-06-19 07:00AM  
Aug-05-19 12:21PM  
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which has completed Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. The company was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Drechsler Andrew TChief Financial OfficerSep 02Buy11.722,00023,44020,000Sep 02 05:00 PM
Ramos EleanorChief Medical OfficerSep 02Buy12.062993,60664,799Sep 02 07:43 PM
Leon FranciscoChief Scientific OfficerAug 21Buy13.352,00026,7082,567,450Aug 21 04:05 PM
Ramos EleanorChief Medical OfficerAug 20Buy13.232,50033,07564,500Aug 20 06:52 PM
Palmer AshleighPresident and CEOAug 18Buy12.695006,3452,566,300Aug 18 06:10 PM
Palmer AshleighPresident and CEOAug 17Buy12.832,80035,9242,565,800Aug 17 07:20 PM
Drechsler Andrew TChief Financial OfficerAug 13Buy13.011,75022,76818,000Aug 13 07:01 PM
Leon FranciscoChief Scientific OfficerJun 24Buy15.432,00030,8622,565,450Jun 24 04:22 PM